03-Jun-2009 - The Wellcome Trust

Oxford Gene Technology successfully completes world's largest copy number variation study

Oxford Gene Technology (OGT) has successfully completed processing more than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium (WTCCC), the world’s largest CNV study involving a collaboration of 24 human geneticists. The project analysed DNA samples from patients to identify genetic variants that play a role in various human diseases, including bipolar disorder, Crohn’s disease, coronary artery disease, type 1 and 2 diabetes, rheumatoid arthritis, breast cancer and hypertension.

OGT processed over 20,000 samples in 20 weeks, using state-of-the-art automated processing to achieve exceptional data quality from whole-genome human CNV-focussed microarrays developed by Agilent. According to the company, over 40 quality control checks have been performed and recorded for each sample during the workflow, producing documented evidence of the excellent QC metrics that have been met.

"In order to characterise genetic variants, reproducible performance and reliable processing of the high resolution microarrays is essential. This project demanded high quality data generated to tight deadlines, and we were very pleased with its rapid progress," said Dr Matt Hurles of the Wellcome Trust Sanger Institute. "Our preliminary estimate is that approximately 20-30 % of the ~11,000 loci targeted on the array we have designed are both polymorphic in our British study population and provide sufficient data quality to assign integer copy numbers to individuals."

Facts, background information, dossiers
  • Wellcome Trust
  • OGT
  • rheumatoid arthritis
  • breast cancer
  • bipolar disorder
More about Wellcome Trust
More about Oxford Gene Technology
  • News

    New test could identify resistant tuberculosis faster

    The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team. This could help health service providers to better treat disease, control transmission of this infectio ... more

    OGT opens New York office and appoints US sales team

    Oxford Gene Technology (OGT) announced that it has opened a new office in Tarrytown, New York to support and grow its cytogenetics arrays and next generation sequencing business in the US.The new office will enable OGT to provide hands-on technical support and training to its existing US cu ... more

    Oxford Gene Technology and Abcodia form Partnership

    Oxford Gene Technology (OGT) has announced a collaborative agreement with Abcodia aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from individuals up to 7 ... more